These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24578536)

  • 21. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study.
    Menzin J; Boulanger L; Hauch O; Friedman M; Marple CB; Wygant G; Hurley JS; Pezzella S; Kaatz S
    Ann Pharmacother; 2005 Mar; 39(3):446-51. PubMed ID: 15701783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality of warfarin control in atrial fibrillation patients in South East Queensland, Australia.
    Bernaitis N; Badrick T; Davey AK; Anoopkumar-Dukie S
    Intern Med J; 2016 Aug; 46(8):925-31. PubMed ID: 27040159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
    Pokorney SD; Holmes DN; Thomas L; Fonarow GC; Kowey PR; Reiffel JA; Singer DE; Freeman JV; Gersh BJ; Mahaffey KW; Hylek EM; Naccarelli GV; Ezekowitz MD; Piccini JP; Peterson ED;
    JAMA Cardiol; 2019 Aug; 4(8):756-764. PubMed ID: 31268487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Baseline Stroke Risk and Bleeding Risk on Warfarin International Normalized Ratio Control in Atrial Fibrillation (from the TREAT-AF Study).
    Hellyer JA; Azarbal F; Than CT; Fan J; Schmitt SK; Yang F; Frayne SM; Phibbs CS; Yong C; Heidenreich PA; Turakhia MP
    Am J Cardiol; 2017 Jan; 119(2):268-274. PubMed ID: 27836133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time in therapeutic range values of patients using warfarin and factors that influence time in therapeutic range.
    Dinç Asarcıklı L; Kafes H; Şen T; Gucuk İpek E; Cebeci M; Gül M; Kanat S; Temizhan A
    Turk Kardiyol Dern Ars; 2021 Sep; 49(6):463-473. PubMed ID: 34523594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT).
    Smith DE; Xuereb CB; Pattison HM; Lip GY; Lane DA
    BMC Cardiovasc Disord; 2010 May; 10():21. PubMed ID: 20487528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Underutilization of warfarin in older persons with chronic nonvalvular atrial fibrillation at high risk for developing stroke.
    Mendelson G; Aronow WS
    J Am Geriatr Soc; 1998 Nov; 46(11):1423-4. PubMed ID: 9809766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation.
    Liu S; Li X; Shi Q; Hamilton M; Friend K; Zhao Y; Horblyuk R; Hede S; Shi L
    Curr Med Res Opin; 2018 Mar; 34(3):415-421. PubMed ID: 28945114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: A multicentre, prospective study.
    Selby R; Kaus L; Sealey F; Koo M; Parpia S; Chan B; Seung SJ; Bradley C; Strauss R; Mittmann N
    PLoS One; 2023; 18(4):e0284425. PubMed ID: 37071625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
    Kwong WJ; Kamat S; Fang C
    Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation. - A multicenter study of its status and infuential factors-.
    Okumura K; Komatsu T; Yamashita T; Okuyama Y; Harada M; Konta Y; Hatayama T; Horiuchi D; Tsushima E
    Circ J; 2011; 75(9):2087-94. PubMed ID: 21737950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry.
    Lehto M; Niiranen J; Korhonen P; Mehtälä J; Khanfir H; Hoti F; Lassila R; Raatikainen P
    Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):657-665. PubMed ID: 28317274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modeling patients' time, travel, and monitoring costs in anticoagulation management: societal savings achievable with the shift from warfarin to direct oral anticoagulants.
    Leminen A; Pyykönen M; Tynkkynen J; Tykkyläinen M; Laatikainen T
    BMC Health Serv Res; 2019 Nov; 19(1):901. PubMed ID: 31775847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease.
    Yang F; Hellyer JA; Than C; Ullal AJ; Kaiser DW; Heidenreich PA; Hoang DD; Winkelmayer WC; Schmitt S; Frayne SM; Phibbs CS; Turakhia MP
    Heart; 2017 Jun; 103(11):818-826. PubMed ID: 27852694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia.
    Jacobs V; Woller SC; Stevens S; May HT; Bair TL; Anderson JL; Crandall BG; Day JD; Johanning K; Long Y; Mallender C; Olson JL; Osborn JS; Weiss JP; Bunch TJ
    Heart Rhythm; 2014 Dec; 11(12):2206-13. PubMed ID: 25111326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?
    Laliberté F; Pilon D; Raut MK; Nelson WW; Olson WH; Germain G; Schein JR; Lefebvre P
    Curr Med Res Opin; 2014 Aug; 30(8):1521-8. PubMed ID: 24758611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
    O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and predictors of warfarin use in patients with atrial fibrillation at low or intermediate risk and relation to thromboembolic events.
    Chae SH; Froehlich J; Morady F; Oral H
    Clin Cardiol; 2011 Oct; 34(10):640-4. PubMed ID: 21994084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time in therapeutic range and stability over time for warfarin users in clinical practice: a retrospective cohort study using linked routinely collected health data in Alberta, Canada.
    McAlister FA; Wiebe N; Hemmelgarn BR
    BMJ Open; 2018 Jan; 8(1):e016980. PubMed ID: 29382672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.